Comparing Methods for Assessing Oestrogen Receptors in Breast Cancer
Author Information
Author(s): DM Barnes, WH Harris, P Smith, RR Millis, RD Rubens
Primary Institution: Imperial Cancer Research Fund, Clinical Oncology Unit, Guy's Hospital, London, UK
Hypothesis
Which method of assessing oestrogen receptor staining correlates best with clinical outcomes in breast cancer patients?
Conclusion
Immunohistochemical assays for oestrogen receptors provide more clinically relevant results than traditional cytosol assays.
Supporting Evidence
- Immunohistochemical assays showed a higher percentage of ER-positive cases compared to cytosol assays.
- 51% of patients showed a complete or partial response to tamoxifen treatment.
- Statistical analysis indicated significant correlations between ER status and clinical outcomes.
- Different scoring methods for immunohistochemistry yielded varying results, highlighting the need for standardization.
Takeaway
This study looked at different ways to check for a protein in breast cancer that helps doctors decide on treatment. They found that one new method works better than the old one.
Methodology
The study involved staining breast cancer tissue from 170 women with tamoxifen treatment using various methods to assess oestrogen receptor status and comparing these results with clinical outcomes.
Potential Biases
Potential bias in patient selection as only those with evaluable metastatic breast cancer were included.
Limitations
The study was limited to women who had already shown a response to hormone treatment, which may not represent the general population of breast cancer patients.
Participant Demographics
170 women with metastatic breast cancer, including 133 with operable primary disease, 23 with locally advanced disease, and 14 with distant metastases.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website